Rights and permissions
About this article
Cite this article
FDA review of Arcoxia and Prexige shows potential CV risk. Inpharma Wkly. 1474, 17 (2005). https://doi.org/10.2165/00128413-200514740-00044
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200514740-00044